Soleno Therapeutics, Inc. (SLNO) NASDAQ
53.01
+0(+0.00%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
53.01
+0(+0.00%)
Currency In USD
| Previous Close | 53.01 |
| Open | 52.99 |
| Day High | 53.01 |
| Day Low | 52.98 |
| 52-Week High | 90.32 |
| 52-Week Low | 29.43 |
| Volume | 4.97M |
| Average Volume | 3.45M |
| Market Cap | 2.76B |
| PE | 27.47 |
| EPS | 1.93 |
| Moving Average 50 Days | 45.78 |
| Moving Average 200 Days | 51.16 |
| Change | 0 |
Data not available
Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer
GlobeNewswire Inc.
Feb 26, 2026 1:00 PM GMT
REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Ful
Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET
GlobeNewswire Inc.
Feb 11, 2026 1:00 PM GMT
REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourt
Soleno Therapeutics to Participate in Upcoming Conferences
GlobeNewswire Inc.
Jan 29, 2026 1:00 PM GMT
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in t